Talmadge E. King Jr, MD

Dean-SOM/VC-Medical Affairs

Dr. Talmadge E. King, Jr. was named dean of the UCSF School of Medicine and vice chancellor for medical affairs in May of 2015. He began his career at UCSF in 1997 as chief of Medical Services at Priscilla Chan and Mark Zuckerberg San Francisco General Hospital and Trauma Center. From 2006 to 2015, he served as chair of the UCSF Department of Medicine, the largest department in the school, with approximately 29 percent of the school's full-time faculty.

A physician-scientist, King’s research has focused on inflammatory and immunologic lung injury. He is best known for his pioneering work in the management of the interstitial pneumonias, a scarring process that often leads to death. His bibliography comprises more than 300 publications and he has co-edited eight books, including the acclaimed reference book, "Interstitial Lung Disease," now in its fifth edition.

King graduated from Gustavus Adolphus College and earned his medical degree at Harvard Medical School, followed by a residency at Emory University Affiliated Hospitals in Atlanta, Ga. and a pulmonary fellowship at the University of Colorado Health Sciences Center in Denver.

He is a member of the Institute of Medicine of the National Academy of Sciences, American Academy of Arts and Sciences, Association of American Physicians, American Clinical and Climatological Association and the Fleischner Society. He is a master of the American College of Physicians and fellow of the American College of Chest Physicians. He won the 2007 Trudeau Medal, the highest honor of the American Thoracic Society.

Education
2018 - Diversity, Equity, and Inclusion Champion Training, University of California
Fellowship, 1979 - Pulmonary/Critical Care, University of Colorado Medical Cente
Residency, 1977 - Internal Medicine, Emory University
M.D., 1974 - School of Medicine, Harvard University
Honors and Awards
  • 2016 APM Robert H. Williams, MD, Distinguished Chair of Medicine Award, Association of Professors of Medicine (APM), 2016
  • Breathing for Life Award, Foundation of the American Thoracic Society, 2012
  • Sesquicentennial Award, Gustavus Adolphus College, 2012
  • Fellow, American Academy of Arts and Sciences, 2011
  • Master, American College of Physicians, 2010
  • Alumni Citation, Gustavus Alumni Association, Gustavus Adolphus College, 2008
  • Trudeau Medal, American Thoracic Society, 2007
  • Member, Institute of Medicine, National Academy of Sciences, 2004
  • PAR Excellence Award, Public Advisory Roundtable of the American Thoracic Society, 2003
  • Member, Association of American Physicians, 1998
  • Elected honorary member, California Thoracic Society, 1998
  • Member. Colorado Pulmonary Hall of Fame, Colorado Thoracic Society, American Lung Association of Colorado, 1998
  • Member, The Fleischner Society, 1997
  • Member, Western Association of Physicians, 1993
  • James J. Waring Award For Outstanding Leadership in the Treatment of Lung Disease, American Lung Association of Colorado, 1992
  • Fellow, American College of Physicians, 1986
  • Fellow, American College of Chest Physicians, 1984
  • First Decade Award for Early Achievement, Alumni Association, Gustavus Adolphus College, 1980
  • Guild of St. Ansger Honor Society, Gustavus Adolphus College, 1970
Websites
Publications
  1. NIH Workshop Report: E-cigarette or Vaping Product Use Associated Lung Injury (EVALI): Developing a Research Agenda.
  2. How Small Differences in Assessed Clinical Performance Amplify to Large Differences in Grades and Awards: A Cascade With Serious Consequences for Students Underrepresented in Medicine.
  3. Lessons From an Educational Never Event.
  4. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model.
  5. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease.
  6. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia.
  7. Early Experiences After Adopting a Quality Improvement Portfolio Into the Academic Advancement Process.
  8. A diagnostic model for chronic hypersensitivity pneumonitis.
  9. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
  10. Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials.
  11. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
  12. American Thoracic Society-European Respiratory Society Classification of the Idiopathic Interstitial Pneumonias: Advances in Knowledge since 2002.
  13. Survival in interstitial pneumonia with features of autoimmune disease: a comparison of proposed criteria.
  14. Sensitivity Analyses of the Change in FVC in a Phase 3 Trial of Pirfenidone for Idiopathic Pulmonary Fibrosis.
  15. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis.
  16. CT staging and monitoring of fibrotic interstitial lung diseases in clinical practice and treatment trials: a position paper from the Fleischner Society.
  17. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis.
  18. A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials.
  19. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials.
  20. Do all patients with idiopathic pulmonary fibrosis warrant a trial of therapeutic intervention? A pro-con perspective.
  21. Analysis of lung function and survival in RECAP: An open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis.
  22. Treatments for idiopathic pulmonary fibrosis.
  23. Smoking-related idiopathic interstitial pneumonia.
  24. Idiopathic pulmonary fibrosis: CT and risk of death.
  25. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
  26. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis.
  27. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
  28. All-cause mortality rate in patients with idiopathic pulmonary fibrosis. Implications for the design and execution of clinical trials.
  29. Predicting survival across chronic interstitial lung disease: the ILD-GAP model.
  30. Future directions in idiopathic pulmonary fibrosis research. An NHLBI workshop report.
  31. Rheumatoid arthritis associated interstitial lung disease: a review.
  32. Predictors of mortality in rheumatoid arthritis-related interstitial lung disease.
  33. Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis.
  34. 6-Minute walk distance is an independent predictor of mortality in patients with idiopathic pulmonary fibrosis.
  35. Rheumatoid arthritis-associated interstitial lung disease: radiologic identification of usual interstitial pneumonia pattern.
  36. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
  37. Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis.
  38. Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials.
  39. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis.
  40. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials.
  41. Reply: idiopathic pulmonary fibrosis: perspectives on clinically meaningful primary endpoints in phase 3 clinical trials.
  42. Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction.
  43. Prevalence and prognosis of unclassifiable interstitial lung disease.
  44. Prevalence and clinical significance of circulating autoantibodies in idiopathic pulmonary fibrosis.
  45. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology.
  46. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
  47. A multidimensional index and staging system for idiopathic pulmonary fibrosis.
  48. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis.
  49. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials.
  50. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis.
  51. Interstitial lung diseases. Preface.
  52. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference.
  53. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis.
  54. Idiopathic pulmonary fibrosis.
  55. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis.
  56. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
  57. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis.
  58. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
  59. Smoking and subclinical interstitial lung disease.
  60. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference.
  61. Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
  62. Workshop on idiopathic pulmonary fibrosis in older adults.
  63. Low prevalence of chronic beryllium disease among workers at a nuclear weapons research and development facility.
  64. Plasma biomarker profiles in acute exacerbation of idiopathic pulmonary fibrosis.
  65. Does chronic microaspiration cause idiopathic pulmonary fibrosis?
  66. Undifferentiated connective tissue disease-associated interstitial lung disease: changes in lung function.
  67. Clinical decisions. American Board of Internal Medicine maintenance of certification program.
  68. The 6 minute walk in idiopathic pulmonary fibrosis: longitudinal changes and minimum important difference.
  69. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern.
  70. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF.
  71. Multisociety task force recommendations of competencies in Pulmonary and Critical Care Medicine.
  72. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial.
  73. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis.
  74. Bosentan for idiopathic pulmonary fibrosis.
  75. Prognostic significance of bronchoalveolar lavage cellular analysis in scleroderma lung disease.
  76. Idiopathic nonspecific interstitial pneumonia: report of an American Thoracic Society project.
  77. Baseline BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis.
  78. Challenges in pulmonary fibrosis x 5: the NSIP/UIP debate.
  79. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis.
  80. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease.
  81. Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.
  82. Acute exacerbations of idiopathic pulmonary fibrosis.
  83. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease?
  84. Challenges in pulmonary fibrosis. 1: Use of high resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias.
  85. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern.
  86. Current diagnosis and management of idiopathic pulmonary fibrosis: a survey of academic physicians.
  87. Respiratory bronchiolitis-interstitial lung disease: long-term outcome.
  88. Clinical problem-solving. Anchors away.
  89. Idiopathic interstitial pneumonia: do community and academic physicians agree on diagnosis?
  90. Anticoagulant therapy and idiopathic pulmonary fibrosis.
  91. Classification and natural history of the idiopathic interstitial pneumonias.
  92. Current perspectives on the treatment of idiopathic pulmonary fibrosis.
  93. Bronchoalveolar lavage fluid D dimer levels are higher and more prevalent in black patients with pulmonary sarcoidosis.
  94. Achieving diversity in academic internal medicine: recommendations for leaders.
  95. A critical assessment of treatment options for idiopathic pulmonary fibrosis.
  96. COPD: a dust-induced disease?
  97. Idiopathic interstitial pneumonias: CT features.
  98. The clinical course of patients with idiopathic pulmonary fibrosis.
  99. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis.
  100. Clinical advances in the diagnosis and therapy of the interstitial lung diseases.
  101. Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis.
  102. Inequality in health care: unjust, inhumane, and unattended!
  103. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis?
  104. Combined corticosteroid and cyclophosphamide therapy does not alter survival in idiopathic pulmonary fibrosis.
  105. The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis.
  106. The case for diversity in academic internal medicine.
  107. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis.
  108. Idiopathic interstitial pneumonias: progress in classification, diagnosis, pathogenesis and management.
  109. Miscellaneous causes of bronchiolitis: inhalational, infectious, drug-induced, and idiopathic.
  110. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia.
  111. Sarcoidosis following HIV infection: evidence for CD4+ lymphocyte dependence.
  112. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis.
  113. Demystifying idiopathic interstitial pneumonia.
  114. Basic fibroblast growth factor and its receptors in idiopathic pulmonary fibrosis and lymphangioleiomyomatosis.
  115. Future research directions in idiopathic pulmonary fibrosis: summary of a National Heart, Lung, and Blood Institute working group.
  116. Nonspecific interstitial pneumonia and systemic sclerosis.
  117. Racial disparities in clinical trials.
  118. Nonspecific interstitial pneumonitis as the sole histologic expression of hypersensitivity pneumonitis.
  119. Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation.